SCHEMBL21947201

SCHEMBL21947201

CCC(=O)c1cnn2cc(OCCN(C)C)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
THRA P10827 2/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.38
NR1I2 O75469 1/20 0.38
PRKD3 O94806 1/20 0.38
ABCB11 O95342 1/20 0.38
EGFR P00533 1/20 0.38
ESR1 P03372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17324591 0.89 FGFR1 (0.42) HPGDKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL15881956 0.88 KDM4E (0.43) HPGDKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL20250795 0.87 THRA (0.49) THRAESR1THRB
SCHEMBL24247786 0.86 NR1I2 (0.39) HPGDSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15882563 0.86 HPGD (0.52) HPGDKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL20654123 0.85 ROCK2 (0.49) RAB9A
SCHEMBL19997282 0.85 ROCK2 (0.44) HPGDKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL17321454 0.85 KDM4E (0.41) HPGDKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL20646745 0.82 ROCK2 (0.40) SMN1; SMN2MEN1KMT2A
SCHEMBL20646858 0.82 PDE2A (0.37) KDM4ELCKDRD2DRD1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10829501-B2 Spiroheptane salicylamides and related compounds as inhibitors of ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2020-11-10 US disclosed
US-20200131200-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10829501-B2 Spiroheptane salicylamides and related compounds as inhibitors of ROCK ROCK1, MYLK, RHOA HPGD 547/4885KDM4E 2121/4885ALDH1A1 895/4885
US-20200131200-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK ROCK1, MYLK, RHOA HPGD 547/4885KDM4E 2121/4885ALDH1A1 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.